May 18, 2020 / 12:35 PM / 10 days ago

BRIEF-Nantkwest Reports FDA Authorization Of IND Application For Mesenchymal Stem Cell Product For The Treatment Of Severe Covid-19 Patients

May 18 (Reuters) - NantKwest Inc:

* NANTKWEST ANNOUNCES FDA AUTHORIZATION OF IND APPLICATION FOR MESENCHYMAL STEM CELL PRODUCT FOR THE TREATMENT OF SEVERE COVID-19 PATIENTS

* NANTKWEST INC - TRIAL ANTICIPATED TO INITIATE IN LOS ANGELES AREA HOSPITALS IN Q2 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below